GlassScriptPhysician profile
Allison K Wade
NPI 1356518872
$4,339.25
in general payments reported to CMS, 2019-2025
21 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609 · 2022: $636 · 2023: $907 · 2024: $835 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,315.79 | 2021-2025 | |
| Novo Nordisk INC | $1,006.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $409.56 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $288.14 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.87 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $239.67 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $204.98 | 2021-2025 | Trelegy Ellipta |
| Abbott Laboratories | $142.92 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $91.71 | 2021-2022 | |
| Lundbeck LLC | $85.43 | 2025 | Vyepti |
| Sanofi-Aventis U.S. LLC | $45.25 | 2022 | |
| Amgen INC. | $41.17 | 2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $39.82 | 2021 | |
| Exact Sciences Corporation | $32.60 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $28.04 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.00 | 2025 | Xifaxan |
| Currax Pharmaceuticals LLC | $17.57 | 2023 | Contrave, Onzetra Xsail |
| Novartis Pharmaceuticals Corporation | $15.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.80 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.04 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.